Degenerative spondylolisthesis: 10 questions every patient should ask.

The facet joints and the intervertebral disc work together as a three-joint complex. When the disc loses height and hydration, the facet joints bear more load and begin to degenerate. As the facets deteriorate — particularly when they have a more sagittally oriented morphology, which is more common in women — they lose their ability to resist forward shear. The vertebra shifts anteriorly. The posterior ligamentous structures stretch to accommodate, further reducing resistance. Once the slip is established, the canal at that level narrows — degenerative spondylolisthesis is, mechanically, a cause of acquired spinal stenosis. (García-Ramos, 2020; Saremi, 2024)

Degenerative spondylolisthesis is predominantly a disease of adults over 50, is four times more common in women than men (likely related to hormonal and anatomical differences in facet orientation), and increases substantially with age. A critical point: a significant proportion of patients with imaging evidence of spondylolisthesis have no symptoms whatsoever. (Wang, 2017; Kalichman, 2008)

The implication is identical to what we have shown for disc herniations: finding spondylolisthesis on an MRI does not by itself establish that it is the cause of a patient’s symptoms. The slip must correlate with the clinical picture, the neurological examination, and the symptom pattern to guide treatment decisions.

Symptomatic degenerative spondylolisthesis typically presents with neurogenic claudication — the same symptom complex seen in lumbar spinal stenosis: pain, heaviness, or weakness in the legs that worsens with walking and standing, and is relieved by sitting or forward flexion. This occurs because walking in extension reduces the already-narrow canal further. Sitting forward opens it.

Diagnosis is clinical and radiographic. The clinical examination evaluates walking distance, posture, neurological status (strength, reflexes, sensation by dermatome), and provocative tests. Imaging provides the structural confirmation. Standard weight-bearing (standing) X-rays with flexion-extension views are essential — they reveal the true magnitude of the slip and whether it is dynamic (the slip increases with extension and reduces with flexion, indicating mechanical instability). A slip that is reducible on flexion suggests instability that is relevant for surgical planning. (Chaput, 2007; Rangwalla, 2024)

The natural history of degenerative spondylolisthesis is not uniformly progressive. The critical long-term study by Matsunaga et al. (2000) followed 145 patients managed non-surgically for 10 to 18 years: 76% remained stable or improved. Symptomatic worsening occurred in 34%, but only 10% developed new neurological deficits. The slip itself progressed in 30% of patients, but slip progression did not reliably predict symptom progression. This suggests that many patients can be managed conservatively for extended periods without inevitable deterioration. (Matsunaga, 2000; Bydon, 2019)

The SPORT trial (Surgical versus Nonsurgical Treatment for Lumbar Degenerative Spondylolisthesis, Weinstein et al., 2007) is the largest randomized controlled trial on this question. At two years, patients treated surgically had significantly greater improvements in pain, function, and quality of life than those managed conservatively. At four years, the surgical group maintained superior outcomes. This was confirmed in the SPORT observational cohort at eight years. (Weinstein, 2007; Weinstein, 2009; Ilyas, 2019)

This is the central controversy in degenerative spondylolisthesis surgery — and it is not resolved. Four randomized controlled trials published in the New England Journal of Medicine have produced conflicting results, and the debate continues in 2025. Understanding what each trial found, and what it didn’t, is essential for any patient facing this decision.

A 2023 systematic review and meta-analysis by Gadjradj et al. synthesized the available randomized evidence: decompression alone and decompression plus fusion produce equivalent functional outcomes at short- and medium-term follow-up in most patients with stable Grade I degenerative spondylolisthesis. The difference lies in the reoperation rate, which is consistently higher after decompression alone (10–15% within 2–5 years) compared to decompression with fusion. (Gadjradj, 2023; Liang, 2017; Pranata, 2022)

Adjacent segment disease (ASD) refers to the development of new pathology — disc degeneration, stenosis, instability, or spondylolisthesis — at the vertebral levels immediately above or below a fusion. It is the most important long-term consequence of spinal fusion that patients rarely discuss with their surgeons before the decision is made.

The mechanism is biomechanical: a fused segment transfers increased mechanical stress — flexion-extension, rotation, shear — to the adjacent unfused levels. Those levels must now absorb motion that was previously distributed across multiple segments. Over years, this accelerated mechanical demand leads to accelerated degeneration. (Donnally, 2020)

Adjacent segment disease after fusion is not merely a radiographic curiosity — it leads to new symptoms (claudication, radiculopathy, instability) that frequently require additional surgery. Each additional fusion extends the construct, increases the biomechanical stress on the next adjacent level, and compounds the problem. This cascade is a known and documented consequence of fusion that must be part of every pre-surgical discussion. (Donnally, 2020; Takahashi, 2016)

At 2-year follow-up, the available randomized evidence shows equivalent functional outcomes between decompression alone and decompression plus fusion for stable Grade I degenerative spondylolisthesis — as confirmed by the Swedish Stenosis Study and NORDSTEN-DS. The SLIP trial showed superiority of fusion, but enrolled a more specific population and used a strict reoperation threshold that has been questioned. At 5 years and beyond, the evidence becomes thinner. (Försth, 2016; Ghogawala, 2016; Austevoll, 2021)

What is consistently documented is that fusion carries additional perioperative risk: longer operative time, greater blood loss, higher infection risk, and implant-related complications. And it carries the long-term risk of adjacent segment disease detailed in the previous section. A patient who achieves equivalent quality of life with decompression alone avoids all of these. The tradeoff is a higher probability of requiring reoperation at the decompressed level if the slip progresses. The question each patient and surgeon must answer together is: which risk is less acceptable to this specific patient? (Chan, 2019; Dong, 2025)